Dominique Tersago
Chief Tech/Sci/R&D Officer at CANTARGIA AB
Net worth: - $ as of 2024-04-29
Dominique Tersago active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CANTARGIA AB | Chief Tech/Sci/R&D Officer | 2022-07-31 | - |
Career history of Dominique Tersago
Former positions of Dominique Tersago
| Companies | Position | Start | End |
|---|---|---|---|
Exevir Bio BV
 Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Chief Tech/Sci/R&D Officer | 2020-06-30 | 2022-06-30 |
Highlight Therapeutics SL
 Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Chief Tech/Sci/R&D Officer | 2017-03-31 | 2020-02-29 |
| ABLYNX | Chief Tech/Sci/R&D Officer | 2013-06-30 | 2015-10-31 |
Training of Dominique Tersago
| University of Antwerp | Doctorate Degree |
Statistics
International
| Belgium | 4 |
| Sweden | 2 |
| Spain | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 4 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CANTARGIA AB | Health Technology |
| Private companies | 3 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Highlight Therapeutics SL
Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Health Technology |
Exevir Bio BV
Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Health Technology |
- Stock Market
- Insiders
- Dominique Tersago
- Experience
